Brief: Castle Biosciences’ Decisiondx®-Melanoma Test Receives 2022 Medtech Breakthrough Award
27/05/2022 12:01
May 27 (Reuters) - Castle Biosciences Inc CSTL.O :
* CASTLE BIOSCIENCES’ DECISIONDX®-MELANOMA TEST RECEIVES
2022
MEDTECH BREAKTHROUGH AWARD
Source text for Eikon: ID:nBwb9TpzPa
Further company coverage: CSTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million